RxDoctor Payments Data

Caroline Boone

Family · Birmingham, ALNPI 1174276331

Payments from drug & device makers

$887in general payments, 2019–2025

Across 25 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$218
  • Boston Scientific$208
  • Medtronic$133
  • Johnson & Johnson$130
  • Amgen$86
  • Janssen Scientific Affairs, LLC$37
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$887 in reported general payments places this provider in the 60th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$13,155
Medicare patients
157
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$88,166
EntrestoSacubitril/Valsartan73$57,960
JardianceEmpagliflozin46$39,355
Repatha SureclickEvolocumab34$26,977
FarxigaDapagliflozin Propanediol16$10,983
Ranolazine ErRanolazine32$2,765
Metoprolol Succinate98$1,769
Atorvastatin Calcium90$1,412
Potassium Chloride57$900
Isosorbide Mononitrate ErIsosorbide Mononitrate46$767
Carvedilol70$666
Enoxaparin Sodium16$659
Losartan Potassium40$520
ClopidogrelClopidogrel Bisulfate37$513
Furosemide91$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$88,16697 claims
NovartisEntresto$218$57,96073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,415 family providers in Alabama.

Other family in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →